Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database
Abstract
Background: Data on longitudinal bladder cancer (BC) costs are scarce. Objective: To assess the economic burden of non-muscle-invasive bladder cancer (NMIBC) by progression risk groups in France over a 1-yr and 5-yr time horizon after initial diagnosis. Design setting and participants: We used data from the French national prospective COhort to study BLAdder CancEr (COBLAnCE) cohort. A total of 1101 patients diagnosed with a primary NMIBC between 2012 and 2018 were linked with the French National Healthcare System Database. Patients were classified into four risk groups according to the 2021 European Association of Urology risk stratification. Resources used included all BC-related hospitalizations, follow-up visits to urology and oncology clinics and related prescriptions, BC-related imaging procedures, transportation, and sick leaves. Costs were estimated from the perspective of the French health care system over the 5 yr after BC diagnosis. Outcome measurements and statistical analysis: Across risk groups, mean per-patient cost ranged from €5838 to €20 678 and €11 697 to €40 519 over 1 yr and 5 yr, respectively. Surgical hospital stays accounted for 60% of costs in the first year. Over 5 yr, intravesical treatments, surveillance visits, and imaging were major cost drivers, especially among patients at lower risk of progression. Results and limitations: Although claims databases are comprehensive, the economic burden of NMIBC may be underestimated owing to potential incomplete coding. Conclusions: To our knowledge, this is the first national cohort study to provide robust cost estimates for patients with NMIBC stratified according to progression risk groups. These real-world data are particularly awaited for the economic evaluation of emerging treatments in patients with NMIBC.
Related
- Awareness and use of ecological and economic evaluation of medical devices in healthcare centers: a survey of French hospitals
- Comparative longitudinal evaluation of DIMS, progressive addition and single-vision lenses on myopia progression, binocular and visual performance in Spanish children
- Evolution of temporomandibular joint-related clinical findings and patient reported quality of life after orthognathic surgery: a prospective multicenter study
- Posttraumatic stress disorder 2 months after induced vaginal delivery: A multicenter prospective study
- Clinical outcomes and predictors of poor prognosis among children with probable and confirmed bacterial meningitis in Northwest Ethiopia: a prospective multicenter cohort study
BibTeX
@article{fraslin2026longitudinal,
title = {{Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database}},
author = {Aldéric M Fraslin and Simone Benhamou and Thierry Lebret and Yann Neuzillet and Stéphane Droupy and Grégoire Poinas and Dimitri Vordos and Laurent Guy and Gautier Marcq and Marc Schneider and Patrick Coloby and Arnaud Monges and Arnaud Méjean and Eric Potiron and Jean-Luc Descotes and Pascal Eschwege and Guillaume Loison and Clémentine Krucker and Anthony Mangin and François Radvanyi and Yves Allory and Maryam Karimi and Julia Bonastre},
journal = {European Urology Open Science},
year = {2026},
month = sep,
doi = {10.1016/j.euros.2026.08.005},
url = {https://inserm.hal.science/inserm-05757662v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database
AU - Aldéric M Fraslin
AU - Simone Benhamou
AU - Thierry Lebret
AU - Yann Neuzillet
AU - Stéphane Droupy
AU - Grégoire Poinas
AU - Dimitri Vordos
AU - Laurent Guy
AU - Gautier Marcq
AU - Marc Schneider
AU - Patrick Coloby
AU - Arnaud Monges
AU - Arnaud Méjean
AU - Eric Potiron
AU - Jean-Luc Descotes
AU - Pascal Eschwege
AU - Guillaume Loison
AU - Clémentine Krucker
AU - Anthony Mangin
AU - François Radvanyi
AU - Yves Allory
AU - Maryam Karimi
AU - Julia Bonastre
PY - 2026
DA - 2026/09/04
JO - European Urology Open Science
DO - 10.1016/j.euros.2026.08.005
UR - https://inserm.hal.science/inserm-05757662v1
AB - Background: Data on longitudinal bladder cancer (BC) costs are scarce. Objective: To assess the economic burden of non-muscle-invasive bladder cancer (NMIBC) by progression risk groups in France over a 1-yr and 5-yr time horizon after initial diagnosis. Design setting and participants: We used data from the French national prospective COhort to study BLAdder CancEr (COBLAnCE) cohort. A total of 1101 patients diagnosed with a primary NMIBC between 2012 and 2018 were linked with the French National Healthcare System Database. Patients were classified into four risk groups according to the 2021 European Association of Urology risk stratification. Resources used included all BC-related hospitalizations, follow-up visits to urology and oncology clinics and related prescriptions, BC-related imaging procedures, transportation, and sick leaves. Costs were estimated from the perspective of the French health care system over the 5 yr after BC diagnosis. Outcome measurements and statistical analysis: Across risk groups, mean per-patient cost ranged from €5838 to €20 678 and €11 697 to €40 519 over 1 yr and 5 yr, respectively. Surgical hospital stays accounted for 60% of costs in the first year. Over 5 yr, intravesical treatments, surveillance visits, and imaging were major cost drivers, especially among patients at lower risk of progression. Results and limitations: Although claims databases are comprehensive, the economic burden of NMIBC may be underestimated owing to potential incomplete coding. Conclusions: To our knowledge, this is the first national cohort study to provide robust cost estimates for patients with NMIBC stratified according to progression risk groups. These real-world data are particularly awaited for the economic evaluation of emerging treatments in patients with NMIBC.
SN - 2666-1683
ER -